Quick comparison
| Peptide | Class | Evidence | Status |
|---|---|---|---|
| Semax | ACTH analog peptide | Moderate | Not FDA-approved, gray-market/compounded, under 2026 FDA scrutiny |
| Selank | Heptapeptide (tuftsin analog) | Moderate | Not FDA-approved, sold via compounding pharmacies and gray-market vendors |
| Dihexa | Small peptide, BDNF/HGF pathway analog | Limited | Not FDA-approved; marketed through wellness and compounding clinics |
| MOTS-C | Mitochondrial-derived peptide | Emerging | Not FDA-approved, research use only |
| BPC-157 | Pentadecapeptide | Limited | Not FDA-approved, sold via compounding pharmacies |
| DSIP | Neuropeptide (Delta Sleep-Inducing Peptide) | Limited | Not FDA-approved, named in 2026 regulatory scrutiny |
The ranking
Semax
Semax is a synthetic peptide derivative of adrenocorticotropic hormone (ACTH), most consistently named across editorial and clinic sources as a top cognitive peptide, often alongside Selank.
It is associated with increased BDNF, and editorial sources link it to focus, stress-resilience, neuroprotection, hypoxia protection, and stroke/cerebrovascular recovery, along with ADHD support and diabetic neuropathy and glaucoma optic neuropathy applications.
The evidence base is largely Russian clinical use and animal-model mechanistic research rather than robust human trials in healthy adults, and Semax is also noted to stabilize enkephalins, which are tied to attention, short-term memory, and emotional regulation.
Strengths
- Most frequently named "top" cognitive peptide across multiple editorial sources
- Mechanistic link to BDNF and neuroprotection (animal/clinical-use based)
- Long history of use in Russian clinical settings for stroke and cerebrovascular recovery
Limitations
- Evidence is largely Russian clinical and animal research, not robust healthy-human trials
- Not FDA-approved; sourced through compounding pharmacies or gray-market channels
- Facing named 2026 FDA regulatory scrutiny
- Best for
- Focus and stress-resilience support under clinical supervision
- Evidence
- Moderate
- Status
- Not FDA-approved, gray-market/compounded, under 2026 FDA scrutiny
Selank
Selank is a synthetic peptide structurally related to tuftsin, an immune-signaling peptide, and is consistently named alongside Semax as one of the two most-recommended cognitive peptides across clinic and wellness sources.
It is described as anxiolytic, modulating serotonin and dopamine balance, and is said to support memory and learning while also being used as an alcohol-withdrawal aid and immune regulator, according to editorial sources.
A distinguishing mechanistic claim, noted by one clinic source, is that Selank and Semax both stabilize enkephalins, which are linked to attention, short-term memory, and emotional regulation.
As with Semax, human clinical trial evidence was not identified in the reviewed research; claims rest on editorial and clinic sourcing rather than the peer-reviewed animal or human studies anchoring this guide’s mechanism sections.
Strengths
- Frequently paired with Semax as a top-tier named cognitive peptide across multiple clinic sources
- Proposed dual action on anxiety and memory/learning via serotonin, dopamine, and enkephalin pathways
- Available in multiple administration formats (injection, nasal spray, oral) per clinic sourcing
Limitations
- No human clinical trial data identified in the reviewed research; claims are editorial/clinic-sourced, not peer-reviewed
- Long-term safety data is limited per multiple sources
- Requires medical supervision and licensed compounding for sourcing and dosing accuracy
- Best for
- Stress-related focus and mild anxiety alongside Semax use
- Evidence
- Moderate
- Status
- Not FDA-approved, sold via compounding pharmacies and gray-market vendors
Dihexa
Dihexa is described in clinic marketing (Huemn, Yoo Direct Health) as a “neurogenic wonder drug” that acts on the BDNF/HGF pathway, the same growth-factor signaling implicated in synaptic plasticity research elsewhere in the peptide literature.
Its rationale borrows credibility from a body of animal-model work showing that BDNF-linked peptides can support synapse formation and memory in rodents, but none of the sourced peer-reviewed research (Asua et al., Autio et al.) actually studies Dihexa itself.
What exists on Dihexa comes almost entirely from clinic and brand copy rather than independent human or animal trial data. It ranks here because the mechanistic story is plausible on paper, yet the compound-specific evidence base is essentially absent.
Strengths
- Mechanistic link to BDNF/HGF pathway, a signaling route with independent (though rodent-based) support for cognitive/synaptic effects
- Positioned by clinic sources as a distinct, potent option among "brain peptides," suggesting active commercial interest and continued attention
Limitations
- No human clinical trial data referenced anywhere in the source set; claims originate from clinic marketing, not research literature
- No animal or in-vitro studies specific to Dihexa were identified in the reviewed research
- No dosing, safety, or regulatory clarity available; sourcing appears limited to wellness clinics rather than established pharmacology
- Best for
- Those curious about BDNF/HGF neurogenic mechanisms, not proven enhancement
- Evidence
- Limited
- Status
- Not FDA-approved; marketed through wellness and compounding clinics
MOTS-C
MOTS-C is a mitochondrial-derived peptide that appears in commercial “cognitive stack” listings (Klearmind), typically bundled alongside peptides like BPC-157 and TB-500 rather than presented as a standalone nootropic.
The research document contains no direct cognitive mechanism, no animal-model data, and no human observational data specifically tying MOTS-C to memory, focus, or neuroplasticity. Its inclusion in cognitive-peptide discussions appears to be inferred from its broader metabolic/mitochondrial role rather than from any cited cognition-specific study.
It is ranked here because it is named in commercial peptide stacks but lacks the direct evidence base that anchors higher-ranked compounds like Semax or Selank.
Strengths
- Part of established mitochondrial-peptide research interest cited by clinic sources
- Mentioned alongside other recovery/repair peptides in existing commercial stacks
Limitations
- No direct cognitive mechanism or outcome data present in the research document
- No animal or human studies on cognition specifically cited
- Sourced and dosed only through compounding pharmacies, with no standardized protocol in evidence
- Best for
- Those curious about mitochondrial-metabolic support, not proven cognition
- Evidence
- Emerging
- Status
- Not FDA-approved, research use only
BPC-157
BPC-157 is a pentadecapeptide most often discussed in a repair and recovery context, typically paired with TB-500, rather than as a direct cognitive enhancer. Across the sourced editorial content, it is positioned adjacent to cognition through reduced inflammation and the gut-brain axis, not through a defined nootropic mechanism like BDNF upregulation or neurotransmitter modulation. No source in this research set frames BPC-157 as a primary evidence-based tool for memory, focus, or learning. Its rank here reflects mechanistic plausibility for indirect brain benefit, not demonstrated cognitive efficacy.
Strengths
- Anti-inflammatory and recovery-related positioning may plausibly support gut-brain axis function
- Frequently paired with TB-500 in clinic-offered recovery stacks, reflecting a common combination in the compounded peptide market.
Limitations
- No source presents human or animal evidence tying BPC-157 directly to cognitive performance
- Its cognitive relevance is inferred rather than studied, so any brain-related benefit is anecdotal at best
- Long-term human safety and dosing data are not established in the research reviewed
- Best for
- Recovery-driven support that may indirectly aid mental clarity
- Evidence
- Limited
- Status
- Not FDA-approved, sold via compounding pharmacies
DSIP
DSIP, or Delta Sleep-Inducing Peptide, is named in the research primarily in a regulatory context rather than a performance context: the FDA’s 2026 scrutiny specifically flagged DSIP-related substances alongside Semax and Epitalon, per Mind Lab Pro’s reporting.
No source in this research base provides mechanistic or study data (animal, in-vitro, or human) on DSIP’s effect on memory, focus, or synaptic function.
Its inclusion here rests entirely on the general consensus that sleep quality influences cognitive performance, an inference rather than a demonstrated finding for this specific compound. It ranks low because, unlike Semax or Selank, no editorial or research source offers benefit claims, dosing context, or mechanism detail beyond its name and its regulatory flag.
Strengths
- Plausible downstream relevance to cognition via sleep quality, consistent with the general framing that sleep affects cognitive aging
- Named specifically enough to be tracked by regulators, suggesting some level of market presence and formulation availability
Limitations
- No efficacy data of any study type (animal, in-vitro, or human) appears in the source material for DSIP specifically
- Cited mainly for FDA regulatory scrutiny in 2026, not for benefit evidence
- No dosing, administration route, or safety profile detail available in the research
- Best for
- Sleep quality support with only indirect cognitive rationale
- Evidence
- Limited
- Status
- Not FDA-approved, named in 2026 regulatory scrutiny
How we picked
Each peptide was ranked by weighing mechanistic plausibility against the strength and species of supporting evidence, whether human data exists at all, and how clearly sources distinguished proven effects from marketing claims.
Semax and Selank rank highest because they have the most consistent mechanistic detail and “some human observational/clinical use in specific patient populations (e.g., stroke, diabetic neuropathy) alongside animal research, though rigorous human clinical trial data is lacking”, while Dihexa, MOTS-c, BPC-157, and DSIP rank lower due to thin, indirect, or absent cognitive-specific data.
This ranking is not an endorsement, and none of these compounds are FDA-approved for cognitive enhancement.
Important safety note
Most of these peptides are sold as research-use-only or compounded products, and long-term human safety data is limited across the board. Reported short-term effects noted in source material include mild headache and temporary fatigue during adaptation, but individual response varies. Anyone considering these compounds should involve a qualified clinician for evaluation and monitoring rather than pursuing them independently.
Frequently asked questions
Which peptide has the strongest evidence for cognitive benefit?
Semax and Selank are the most consistently cited in research and clinic sources, with mechanistic data on BDNF and enkephalin stabilization. Most of this evidence comes from Russian clinical and animal research rather than large controlled human trials.
Is BPC-157 good for memory or focus?
Not directly. Sources position BPC-157 as supporting cognition only indirectly, through reduced inflammation and recovery effects, not through a described gut-brain axis mechanism., not as a primary cognitive enhancer with its own evidence base.
Does MOTS-c actually improve cognition?
There is no direct cognitive mechanism or outcome data for MOTS-c in the research reviewed. It appears in cognitive stacks as a mitochondrial-support peptide, not one with established brain-specific evidence.
Why is Dihexa ranked low despite a compelling mechanism?
Its rationale through the BDNF/HGF pathway is scientifically plausible, but human data is essentially absent. Most of what is available comes from branded clinic marketing rather than independent research.
What is DSIP and why isn't it higher on the list?
DSIP is a sleep-related peptide whose cognitive relevance would come indirectly through improved sleep quality. It is discussed more in the context of regulatory scrutiny than in efficacy data.
Are any of these peptides FDA-approved for cognitive use?
No. None of the peptides in this ranking are FDA-approved for cognitive enhancement, and several face active regulatory scrutiny regarding how they are sourced and marketed.
Are these peptides legal to buy and use?
Many are sold as research-use-only or through compounding pharmacies, occupying a regulatory gray zone rather than being clearly approved consumer products. This is a key reason medical supervision is repeatedly emphasized in source material.